Tiny study tests radiation boost to immunotherapy in Hard-to-Treat cancers
NCT ID NCT04620603
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether adding low-dose radiation (brachytherapy) to standard immunotherapy could help shrink tumors in people with advanced melanoma, kidney cancer, or urothelial cancer. Only 5 participants were enrolled, and the main goal was to see how many responded to treatment. Because it is so small, the results are very preliminary and cannot yet guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Low-dose brachytherapy (radiation) plus standard immunotherapy (immune checkpoint inhibitor)
- What this could lead to
- If it works, this could point toward a way to make immunotherapy more effective by adding targeted radiation directly to tumors.
- What could go wrong
- This is a very early, tiny pilot study with only 5 people. It is too small to draw firm conclusions, and the combination may not improve outcomes or could increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, 44122, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral drug targets Cancer's growth engine in advanced tumours
- Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
- Kidney cancer patients in Real-World clinics get immunotherapy: does it work?
- New drug combo aims to tackle Hard-to-Treat HER2 cancers
- New drug YH32364 targets Hard-to-Treat cancers in first human trial
- New drug cocktail aims to outperform chemo for advanced bladder cancer